"there are very few normal-weight individuals in the abnormal waist circumference group"; 5) in discussing a report (3) claiming that "BMI and particularly waist circumference were both strongly linked to cardiovascular disease and especially to diabetes", G. M. Reaven correctly disagrees by concluding that BMI and waist circumference links to these pathologies do not differ substantially; 6) he asks next, "is there any clinical benefit in differentiating patients with Type 2 DM on the basis of whether they also qualify for the metabolic syndrome: type 2DM with metabolic syndrome versus type 2 DM without metabolic syndrome?"; His answer was "that all cardiovascular disease risk factors should be individually and aggressively treated"; 7) Reaven confesses "the ability of the metabolic syndrome to identify individuals at risk for type 2 DM and/or cardiovascular disease is no better than its competent parts", namely, each parameter utilized to define metabolic syndrome; 8) "none of this information (on the metabolic syndrome) has provided new pathophysiological insight, nor does it support the clinical utility of the metabolic syndrome as a diagnostic category"; 9) "if a patient meets the diagnosis criteria for diabetes mellitus type 2 or essential hypertension, does knowing whether or not they also meet the criteria for the metabolic syndrome going to affect the treatment plan?"; He concludes against this possibility by adding the question "is there any reason why the metabolic syndrome category should not be given its well-deserved rest?"; 10) "there is no evidence that a diagnosis of the metabolic syndrome improves our ability to identify individuals at increased risk of type 2 DM or cardiovascular disease"; and 11) "the Framingham Risk Study provides a more useful way to identify individuals at risk for cardiovascular disease than the metabolic syndrome".
To all of these wise arguments, I add that, in my practice, I have cared about fasting blood glucose, triglycerides, HDL, and arterial blood pressure and I am aware that each one of them may be under some genetic control or environmental influence, and that cardiovascular protection can be effectively reached despite not taking into account the patient's waist circumference. How misguided were those who considered that by adding the latter parameter to the other ones, which are controlled by multiple genes, a single gene might explain the whole syndrome! Reaven's conclusions redeem the sins of many, such as I, who have treated their patients solely on the basis of canonical criteria (like those of the Framingham and PROCAM metrics, as well as a few other metrics), which include conventional, major risk factors for cardiovascular disease, such as age, gender, hypertension, smoking, lipid values, diabetes, and family history, and who have cared about body mass index only when it was connected with one of the aforementioned major risk factors. I dare to further argue that I belong to that category of skeptics who seldom bother about homocysteine, C reactive protein, and minor cardiovascular risk factors when dealing with patients under my care. I am happy to confess that I have neither told medical residents that I had to label someone as having "the syndrome", nor that this was necessary to prevent him or her from developing new, or aggravating his or her preexisting cardiovascular disease.
I recall that some of my peers at major international meetings used to hotly discuss metabolic syndrome when they attended important conferences on the topic. But in private, they candidly confessed that they cared far more about measuring the ankle/brachial blood pressure index (a regrettably neglected procedure in our country!) than they bothered about labeling the patient in the metabolic syndrome category. Although I risk being impolite, I disclose here the answer I got from G. M. Reaven, many years ago, at an international meeting; if I recall correctly, it was something like "you do not understand what I am presenting here". I am now quite glad that he has finally understood what he and others had been writing about for so many years.
Before drawing the premature conclusion that science indeed progresses through the waste of money, and although Reaven's conclusions are likely to be devastating to those who for years have been enthusiastic about the usefulness of the metabolic syndrome concept, we should not be that pessimistic. While searching for its etiology, much has been learned about the role of adipose tissue in inflammation and physiology, the mechanisms of insulin resistance, adipose tissue as an endocrine organ, and certainly much more. However, I have to say that I felt that metabolic syndrome had already passed its time many years ago. I extend my condolences and sympathies for the tears of the many metabolic syndrome widows and destitute orphans who have been left behind.
